Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan

Okawa, Tomohiko; Dokiya, Takushi; Nishio, Makoto; Hishikawa, Yoshio; Morita, Kozo

doi:10.1016/s0360-3016(99)00253-9

Cited by 81 publications

(49 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumor length was a signi cant prognostic factor in patients with esophageal carcinoma treated with ERT alone (5,8). In our study, patients whose tumor length was 5 cm or less had signi cantly better CR and survival rates than those with tumors of more than 5 cm in length.…”

Section: Discussionmentioning

confidence: 45%

See 1 more Smart Citation

Results of External Irradiation and Low-Dose-Rate Intraluminal Brachytherapy for Esophageal Cancer

et al. 2002

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 45%

“…Thus intraluminal brachytherapy (ILBT) has been used in addition to external irradiation (ERT) and better results than those obtained with ERT alone have been reported (5,6). However, the optimal doses of ERT and ILBT are still unclear.…”

mentioning

confidence: 99%

Results of External Irradiation and Low-Dose-Rate Intraluminal Brachytherapy for Esophageal Cancer

et al. 2002

View full text Add to dashboard Cite

“…mucosal surface or certain distance from the central line of the applicator) in various institutions, as reported in Ref. [35]. For instance, it was reported in the long-term experience with esophageal brachytherapy treatment [36] that radiation was delivered at a level of 5 mm below the surface of the mucosa.…”

Section: Brachytherapy Of Esophageal Cancermentioning

confidence: 99%

Radiation Therapy for Esophageal Cancer

Buzurović¹,

Daróczi²,

O’Farrell³

et al. 2017

Esophageal Abnormalities

View full text Add to dashboard Cite

Esophageal cancer develops in the mucosa of the esophagus and spreads toward the muscle layer. The nonsurgical treatment for localized, deeply invasive esophageal cancer has been external beam radiation therapy (EBRT) and concurrent chemotherapy. Recently, intraluminal brachytherapy showed a strong potential for the improvement of the therapeutic ratio. It was found that the fractionated high dose rate (HDR) brachytherapy ofered beneicial palliation for a longer period of time with more durable symptom control. A similar was concluded for advanced unresectable esophageal cancer in previously irradiated patients. HDR brachytherapy may be a useful salvage treatment option for inoperable patients diagnosed with local esophageal cancer. Although beter local control can be achieved with higher brachytherapy dose, this increases the risk of acute morbidity and late morbidity, especially in the seting of recurrence cancer. It was found that the moderate dose of EBRT and HDR brachytherapy could give a beter local response than EBRT alone.

show abstract

“…A radioactive source is placed intraluminally via bronchoscopy or a nasogastric tube. Brachytherapy has been used both as primary therapy (usually as a palliative modality) (Moni et al, 1996;Sur et al, 1992Sur et al, , 1998Jager et al, 1995;Maingon et al, 2000) and as boost after external-beam radiation therapy or combined modality therapy (Armstrong, 1993;Calais et al, 1997;Akagi et al, 1999;Schraube et al, 1997;Okawa et al, 1999). It can be delivered either by high dose rate or low dose rate (Caspers et al, 1993).…”

Section: Brachytherapymentioning

confidence: 99%